Nisa Investment Advisors
HOWL icon

Nisa Investment Advisors’s Werewolf Therapeutics HOWL Stock Holding History

Nisa Investment Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-345
Closed -$219 – 3083
2025
Q4 		$219 Sell
345
-1,030
-75% -$1.25K ﹤0.01% 2916
2025
Q3 		$2.71K Hold
1,375
– – ﹤0.01% 2555
2025
Q2 		$1.5K Buy
+1,375
New +$1.42K ﹤0.01% 2661
2025
Q1 		– Sell
-40
Closed -$59 – 3018
2024
Q4 		$59 Sell
40
-85
-68% -$173 ﹤0.01% 2992
2024
Q3 		$265 Buy
+125
New +$284 ﹤0.01% 2817

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nisa Investment Advisors's HOWL Position: Q1 2026 in Review

Nisa Investment Advisors sold out of Werewolf Therapeutics (HOWL) in Q1 2026, closing a stake of 345 shares — an estimated $219 sold.

Nisa Investment Advisors first reported a position in HOWL in Q3 2024 and held it in 5 quarters. The position peaked at $2.71K in Q3 2025. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Nisa Investment Advisors reported no remaining Werewolf Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nisa Investment Advisors sold 345 Werewolf Therapeutics shares in Q1 2026, an estimated $219.
  • Nisa Investment Advisors first reported a position in Werewolf Therapeutics in Q3 2024 and held it in 5 quarters.
  • Nisa Investment Advisors's Werewolf Therapeutics position peaked at $2.71K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.